Search results
Results from the WOW.Com Content Network
Catechol. A catecholamine (/ ˌ k æ t ə ˈ k oʊ l ə m iː n /; abbreviated CA) is a monoamine neurotransmitter, an organic compound that has a catechol (benzene with two hydroxyl side groups next to each other) and a side-chain amine. [1] Catechol can be either a free molecule or a substituent of a larger molecule, where it represents a 1,2 ...
However, these antidepressant-like effects may only occur with combination treatment of tolcapone with levodopa and an aromatic L-amino acid decarboxylase inhibitor. [10] In animals, tolcapone by itself does not increase dopamine levels in the striatum , nucleus accumbens , or frontal cortex , but does augment brain L -DOPA levels when combined ...
Norepinephrine degradation. Catechol-O-methyltransferase is shown in green boxes.[5] [6]Catechol-O-methyltransferase (COMT; EC 2.1.1.6) is one of several enzymes that degrade catecholamines (neurotransmitters such as dopamine, epinephrine, and norepinephrine), catecholestrogens, and various drugs and substances having a catechol structure. [7]
Catechol (/ ˈ k æ t ɪ tʃ ɒ l / or / ˈ k æ t ɪ k ɒ l /), also known as pyrocatechol or 1,2-dihydroxybenzene, is an organic compound with the molecular formula C 6 H 4 (OH) 2.It is the ortho isomer of the three isomeric benzenediols.
Tolcapone, sold under the brand name Tasmar, is a medication used to treat Parkinson's disease (PD). It is a selective, potent and reversible nitrocatechol-type inhibitor of the enzyme catechol-O-methyltransferase (COMT). [5] It has demonstrated significant liver toxicity, which has led to suspension of marketing authorisations in a number of ...
Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease. [3] [6] [4] [5] Opicapone is a catechol-O-methyltransferase (COMT) inhibitor.
General side effects for rotigotine may include constipation, dyskinesia, nausea, vomiting, dizziness, fatigue, insomnia, somnolence, confusion, and hallucinations. [12] [13] More serious complications can include psychosis and impulse control disorders like hypersexuality, punding, and pathological gambling. [14]
Pargyline was first described in 1960 [9] [16] [17] and was introduced for medical use in 1963. [18] It was available in the United States and the United Kingdom. [18] [2] [5] The clinical use of pargyline was limited due to its side effects and interactions. [1] The drug remained available in the United States as late as 2000. [5]